 | |
| Clinical data | |
|---|---|
| Trade names | Vanrafia |
| Other names | ABT-627, A-127722, atrasentan hydrochloride (USANUS) |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Endothelin receptor antagonist |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| DrugBank |
|
| ChemSpider | |
| UNII |
|
| KEGG |
|
| ChEBI | |
| ChEMBL |
|
| ECHA InfoCard | 100.206.784 |
| Chemical and physical data | |
| Formula | C29H38N2O6 |
| Molar mass | 510.631 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Atrasentan, sold under the brand nameVanrafia, is amedication used to reduceproteinuria.[1] It is anendothelin receptor antagonist.[1] It is takenby mouth.[1]
Atrasentan was approved for medical use in the United States in April 2025.[1][2]
Atrasentan isindicated to reduceproteinuria in adults with primaryimmunoglobulin A nephropathy at risk of rapid disease progression, generally aurine protein-to-creatinine ratio >= 1.5 g/g.[1]
Atrasentan was approved for medical use in the United States in April 2025.[1][2]
Atrasentan is theinternational nonproprietary name.[3]
Atrasentan is sold under the brand name Vanrafia.[1][2]
Atrasentan failed a phase III trial for prostate cancer in patients unresponsive to hormone therapy.[4] A second trial confirmed this finding.[5]
A study published in 2014 showed that 0.75 mg and 1.25 mg of atrasentan reduced urinary albumin by 35 and 38% respectively with modest side effects. Patients also had decreased home blood pressures (but no change in office readings) decrease total cholesterol and LDL. Patients in the 1.25 mg dose group had increased weight gain which was presumably due to increased edema and had to withdraw from the study more than the placebo or 0.75 mg dose group.[6]
In 2013, the SONAR trial[7] was initiated to determine if atrasentan reduces kidney failure in diabetic kidney disease.[8]
In 2024, the phase III ALIGN trial found atrasentan to be effective in reducingproteinuria in participants withIgA nephropathy.[9][10]
Atrasentan is being studied for the treatment of various types ofcancer,[11] includingnon-small-cell lung cancer.[12] It is also being investigated as a therapy for diabetic kidney disease.[13]
 | Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |
